Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates

Core Insights - Biogen Inc. reported quarterly earnings of $4.81 per share, exceeding the Zacks Consensus Estimate of $3.89 per share, and showing an increase from $4.08 per share a year ago, resulting in an earnings surprise of +23.65% [1] - The company generated revenues of $2.53 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.31% and reflecting a year-over-year increase from $2.47 billion [2] - Biogen has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] Earnings Outlook - The sustainability of Biogen's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.38 on revenues of $2.27 billion, while for the current fiscal year, the estimate is $15.74 on revenues of $9.68 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]